Kelun-Biotech’s Novel Cancer Drug Enters Clinical Trials

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the approval of their innovative drug SKB518 for injection by China’s National Medical Products Administration for clinical trials. SKB518, a novel ADC drug targeting advanced solid tumors, shows promising preclinical efficacy and safety, leveraging the company’s proprietary ‘OptiDC’ platform technology. Shareholders and potential investors are cautioned, however, as the drug’s successful development and commercialization cannot be guaranteed.

For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.